Immunome Inc. announces a proposed public offering of common stock totaling $400 million.
The underwritten public offering is subject to market and other conditions.
The company plans to issue and sell shares of common stock with additional options for underwriters.
Proposed Public Offering
Immunome intends to issue and sell $400 million of common stock with a 30-day option for an additional $60 million for underwriters.
Bookrunning Managers
Leading firms like Leerink Partners, J.P. Morgan, and Goldman Sachs are acting as joint bookrunning managers for the offering.
Shelf Registration Statement
The offering is made pursuant to a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
- Immunome's announcement indicates a strategic move to raise significant capital through the public offering.
- The participation of reputable firms as bookrunning managers suggests confidence in the company's offerings.
The proposed public offering by Immunome Inc. showcases the company's commitment to developing targeted cancer therapies and its confidence in the market conditions.